IL139852A0 - Monoclonal antibodies directed against the g3bp protein, and uses - Google Patents

Monoclonal antibodies directed against the g3bp protein, and uses

Info

Publication number
IL139852A0
IL139852A0 IL13985299A IL13985299A IL139852A0 IL 139852 A0 IL139852 A0 IL 139852A0 IL 13985299 A IL13985299 A IL 13985299A IL 13985299 A IL13985299 A IL 13985299A IL 139852 A0 IL139852 A0 IL 139852A0
Authority
IL
Israel
Prior art keywords
directed against
monoclonal antibodies
antibodies directed
g3bp protein
g3bp
Prior art date
Application number
IL13985299A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of IL139852A0 publication Critical patent/IL139852A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL13985299A 1998-06-17 1999-06-17 Monoclonal antibodies directed against the g3bp protein, and uses IL139852A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9807617A FR2780062B1 (fr) 1998-06-17 1998-06-17 Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
PCT/FR1999/001453 WO1999065947A2 (fr) 1998-06-17 1999-06-17 Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations

Publications (1)

Publication Number Publication Date
IL139852A0 true IL139852A0 (en) 2002-02-10

Family

ID=9527481

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13985299A IL139852A0 (en) 1998-06-17 1999-06-17 Monoclonal antibodies directed against the g3bp protein, and uses
IL139852A IL139852A (en) 1998-06-17 2000-11-23 Monoclonal antibodies directed against the g3bp protein, and uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL139852A IL139852A (en) 1998-06-17 2000-11-23 Monoclonal antibodies directed against the g3bp protein, and uses

Country Status (13)

Country Link
US (1) US7001980B1 (de)
EP (1) EP1087997B1 (de)
JP (1) JP2002518001A (de)
KR (1) KR100694917B1 (de)
CN (1) CN1213070C (de)
AT (1) ATE395363T1 (de)
AU (1) AU764139B2 (de)
CA (1) CA2331151A1 (de)
DE (1) DE69938725D1 (de)
FR (1) FR2780062B1 (de)
HU (1) HUP0103152A3 (de)
IL (2) IL139852A0 (de)
WO (1) WO1999065947A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001266070A1 (en) * 2000-06-16 2001-12-24 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Method for identifying apoptosis-modified proteins
CN1341644A (zh) * 2000-09-07 2002-03-27 上海博德基因开发有限公司 一种新的多肽——人核内非均－核蛋白32.01和编码这种多肽的多核苷酸
AUPR721101A0 (en) * 2001-08-23 2001-09-13 University Of Queensland, The Nucleic acid and polypeptide linked to breast cancer
WO2004001422A2 (en) * 2002-06-20 2003-12-31 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases
DK1641820T3 (da) * 2003-06-30 2008-09-15 Univ Lausanne Fra RasGap afledt peptid til selektiv at dræbe kræftceller
DK2047863T3 (da) 2006-06-08 2013-09-16 Chugai Pharmaceutical Co Ltd Middel til forebyggelse eller behandling af inflammatoriske sygdomme
BRPI0821110B8 (pt) 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
US8853180B2 (en) * 2009-09-10 2014-10-07 Mayo Foundation For Medical Education And Research Methods and materials for modulating deubiquitinases and ubiquitinated polypeptides
CN101921313B (zh) 2010-04-07 2012-02-29 武汉凯泰新生物技术有限公司 治疗或预防癌症的多肽或其衍生产品及应用
CN103517918A (zh) 2011-03-01 2014-01-15 诺沃—诺迪斯克有限公司 拮抗性dr3配体
CA2980992C (en) 2015-04-14 2024-01-23 Akihisa Kaneko Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
CN106771258A (zh) * 2017-02-16 2017-05-31 广州赛太特生物医学科技有限公司 一种半乳糖凝集素‑3结合蛋白的检测试剂盒及其方法和应用
JP6845973B1 (ja) 2019-11-20 2021-03-24 中外製薬株式会社 抗体含有製剤
CN115407063A (zh) * 2021-05-26 2022-11-29 江苏科兴诺生物技术有限公司 一种量子点荧光免疫层析法肿瘤标志物（g3bp）试剂盒及其检测方法
CN113755594B (zh) * 2021-09-26 2024-05-14 中国医学科学院肿瘤医院 一种预测小细胞肺癌辅助化疗获益和识别化疗耐药治疗靶点的系统和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5402648A (en) 1993-07-01 1995-04-04 Apd Cryogenics Inc. Sealed dewar with separate circulation loop for external cooling at constant pressure
IL116026A (en) * 1994-11-22 2005-08-31 Rhone Poulenc Rorer Sa Peptides capable of linking to the sh3 domain of gap, nucleotide sequences encoding the same, their preparation and uses
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method

Also Published As

Publication number Publication date
US7001980B1 (en) 2006-02-21
EP1087997A2 (de) 2001-04-04
FR2780062A1 (fr) 1999-12-24
KR100694917B1 (ko) 2007-03-14
FR2780062B1 (fr) 2000-07-28
DE69938725D1 (de) 2008-06-26
CN1213070C (zh) 2005-08-03
AU764139B2 (en) 2003-08-14
KR20010052942A (ko) 2001-06-25
CA2331151A1 (fr) 1999-12-23
AU4151599A (en) 2000-01-05
WO1999065947A3 (fr) 2000-02-24
HUP0103152A2 (hu) 2001-12-28
EP1087997B1 (de) 2008-05-14
HUP0103152A3 (en) 2004-03-01
CN1305497A (zh) 2001-07-25
ATE395363T1 (de) 2008-05-15
IL139852A (en) 2006-04-10
WO1999065947A2 (fr) 1999-12-23
JP2002518001A (ja) 2002-06-25

Similar Documents

Publication Publication Date Title
GEP20105118B (en) Anti-vegf antibodies
AU1462300A (en) Human pan-hcv human monoclonal antibodies
WO2001049728A3 (en) HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
WO2001014424A3 (en) Human ctla-4 antibodies and their uses
SI1187632T1 (sl) Zdravljenje z anti-ErbB2 protitelesi
WO1999065947A3 (fr) Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
AU6954398A (en) Antagonistic anti-avb3 integrin antibodies
ATE347904T1 (de) Krebsimmuntherapie und krebsdiagnose unter verwendung universeller tumorassoziierter antigene einschliesslich htert
AU3667399A (en) Monoclonal antibodies specific for anthrax spores and peptides derived from the antibodies thereof
WO1996027665A3 (en) Neuron-restrictive silencer factor proteins
WO1999025843A3 (en) Human checkpoint kinase, hcds1, compositions and methods
WO2001012660A3 (en) HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
WO2000029448A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
ATE221204T1 (de) Rezeptorbindungsassay, für den rezeptorbindungsassay geeigneter rekombinanter fusionsrezeptor, vektor zu dessen herstellung sowie reagenziensatz für die durchführung des rezeptorbindungsassays
WO2001004297A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
AU2759899A (en) Purified sperm surface antigen, monoclonal antibody therefor and application therefor
HUP0202270A3 (en) Antitumor antibodies, proteins, and uses thereof
NO974852L (no) Humant <beta>2-integrin-<alfa>-subenhet
DE59611293D1 (de) Protein mit dnase-aktivität
WO1997010258A3 (de) Antikörper gegen an oberflächen von carcinom-zellen ausserhalb von desmosomen exponierte epitope desmosomaler cadherine
AU7478098A (en) Methods of treatment using nbs-1, antibodies and proteins thereto, and uses of the antibodies
EP0667395A4 (de) Monoklonale antikörper, anwendung und verfahren zur herstellung.
WO1999002564A3 (de) Ancrod spezifische monoklonale antikörper, antikörperfragmente, deren mischungen oder derivate und deren verwendung
AU4775899A (en) Human monoclonal antibodies against the tumor antigen uk114 and lymphocyte cellsand hybridomas for their production
TW288020B (en) Monoclonal antibodies specific to methamphetamine, hybridoma producing the antibodies, kits containing the antibodies and uses thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed